Candidemia Pipeline Report provides Therapeutic Assessment of the Key 4+ Pipeline Therapies in this Domain | Major Companies- Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, and others.

DelveInsight’s, “Candidemia Pipeline Insight 2023,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Candidemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Candidemia Emerging drugs, the Candidemia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Candidemia pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Candidemia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Candidemia clinical trials studies, Candidemia NDA approvals (if any), and product development activities comprising the technology, Candidemia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Candidemia Pipeline Report

• DelveInsight’s Candidemia Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Candidemia treatment.
• The leading Candidemia Companies include Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Pfizer, Gilead Sciences, Astellas Pharma Inc, Basilea Pharmaceuticals, Scynexis Inc, and others.
• Promising Candidemia Pipeline Therapies include SCY-078, Voriconazole, Caspofungin, Isavuconazole, Anidulafungin, Caspofungin, Micafungin, Fluconazole, Anidulafungin, and others.
• The Candidemia Companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The Candidemia pipeline therapies under development are focused on novel approaches to treat/improve Candidemia.

To explore more information on the latest breakthroughs in the Candidemia Pipeline treatment landscape of the report, click here @ Candidemia Pipeline Outlook

Candidemia Overview

Candidemia is defined as the presence of Candida species in the blood. It is the most common fungal bloodstream infection in hospitalized patients. Candida albicans is the most common cause of candidemia, representing 35% to 60% of isolates. Candida parapsilosis, Candida tropicalis, Candida glabrata and Candida krusei, are the most common nonalbicans Candida species identified in cultures. Most common risk factors include critical illness and prolonged intensive care unit stay.

Candidemia Emerging Drugs Profile

• Rezafungin: Cidara Therapeutics

Cidara is developing a novel once-weekly echinocandin, rezafungin, for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism, enhancing its efficacy and safety potential for patients. For the treatment of candidemia and invasive candidiasis, rezafungin has designations for Qualified Infectious Disease Product, or QIDP, Fast Track, and Orphan Drug. QIDP and Orphan Drug designations together provide a total of 12 years of marketing exclusivity in the United States from the time of FDA approval. Originally, this compound was owned by Seachaid Pharmaceuticals. Rezafungin acetate is now licensed by Mundipharma International and under the development of Cidara Therapeutics. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Candidemia.

For further information, refer to the detailed Candidemia Unmet Needs, Candidemia Market Drivers, and Candidemia Market Barriers, click here for Candidemia Ongoing Clinical Trial Analysis

Candidemia Pipeline Therapeutics Assessment

There are approx. 4+ key companies which are developing the therapies for Candidemia. The companies which have their Candidemia drug candidates in the most advanced stage, i.e. Phase III include, Cidara Therapeutics.

Candidemia Pipeline: Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request a sample and discover the recent advances in Candidemia Ongoing Clinical Trial Analysis and Medications, click here @ Candidemia Treatment Landscape

Scope of the Candidemia Pipeline Report

• Coverage- Global
• Candidemia Companies- Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Pfizer, Gilead Sciences, Astellas Pharma Inc, Basilea Pharmaceuticals, Scynexis Inc, and others.
• Candidemia Pipeline Therapies- SCY-078, Voriconazole, Caspofungin, Isavuconazole, Anidulafungin, Caspofungin, Micafungin, Fluconazole, Anidulafungin, and others.
• Candidemia Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Candidemia Market Drivers and Candidemia Market Barriers, click here @ Candidemia Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Executive Summary
3. Candidemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Rezafungin: Cidara Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. APX001: Amplyx Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Candidemia Key Companies
17. Candidemia Key Products
18. Candidemia- Unmet Needs
19. Candidemia- Market Drivers and Barriers
20. Candidemia- Future Perspectives and Conclusion
21. Candidemia Analyst Views
22. Candidemia Key Companies
23. Appendix

Got Queries? Find out the related information on Candidemia Mergers and acquisitions, Candidemia Licensing Activities @ Candidemia Emerging Drugs, and Recent Trends

List of Top Selling Market Research Reports in 2023

• Surgical Mask & Respirator Market
• Stem Cell Market
• Schistosomiasis Market
• Ranibizumab Biosimilars Insight
• Percutaneous Arterial Closure Device Market
• Paranasal Sinus Cancer Market
• Oral Electrolyte Solutions Market
• Medical Marijuana Market
• Inflammatory Pain Market
• B-Cell Maturation Antigen Targeted Therapies Market
• Axillary Hyperhidrosis Market
• Complement 3 Glomerulopathy Market
• Etanercept Biosimilar Insight
• Familial Adenomatous Polyposis Market
• Parry-Romberg Syndrome PRS Market
• Systemic Sclerosis-associated Interstitial Lung Disease Market
• Thrombotic Thrombocytopenic Purpura Market
• Varicella Zoster (HHV-3) Infections Market
• Central Retinal Vein Occlusion Market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com